Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055

A Phase I, Open Label, Single-centre Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055 Administered Orally to Japanese Patients With Advanced Solid Tumours

The primary objective is to assess the safety and tolerability of AZD8055 in Japanese patients with advanced solid tumours.

Inclusion Criteria:

• Japanese patients with advanced solid tumors for which suitable effective standard treatment does not exist or is no longer effective
• Relatively good overall health other than cancer

Exclusion Criteria:

• Poor bone marrow function (not producing enough blood cells)
• Poor liver or kidney function
• Serious concomitant illness